Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.

This 3-arm trial in rheumatoid arthritis stopped early because of contractual issues and commissioning challenges, but 122 randomised participants were followed up, generating evidence for future meta-analyses.

https://ift.tt/2MxjDga